Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Corcept Therapeutics (CORT) Accumulated Depreciation & Amortization (2016 - 2023)

Corcept Therapeutics (CORT) has disclosed Accumulated Depreciation & Amortization for 12 consecutive years, with $358000.0 as the latest value for Q2 2023.

  • Quarterly Accumulated Depreciation & Amortization fell 11.39% to $358000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $358000.0 through Jun 2023, down 11.39% year-over-year, with the annual reading at $3.7 million for FY2022, 26.74% up from the prior year.
  • Accumulated Depreciation & Amortization hit $358000.0 in Q2 2023 for Corcept Therapeutics, up from $172000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $3.7 million in Q4 2022 to a low of $172000.0 in Q1 2023.
  • Historically, Accumulated Depreciation & Amortization has averaged $1.0 million across 5 years, with a median of $447000.0 in 2020.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 582.6% in 2021 and later tumbled 83.65% in 2022.
  • Year by year, Accumulated Depreciation & Amortization stood at $703000.0 in 2019, then soared by 163.58% to $1.9 million in 2020, then surged by 57.85% to $2.9 million in 2021, then increased by 26.74% to $3.7 million in 2022, then plummeted by 90.34% to $358000.0 in 2023.
  • Business Quant data shows Accumulated Depreciation & Amortization for CORT at $358000.0 in Q2 2023, $172000.0 in Q1 2023, and $3.7 million in Q4 2022.